Other languages Catalyst Biosciences

Equities

CBIO

US14888D2080

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
14.43 ^USD	+1.33%		-8.38%	+88.15%

2023	Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from NASDAQ Composite Index	CI
2023	Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. in a reverse merger transaction.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. in a reverse merger transaction.	23-10-29
Catalyst Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26
Catalyst Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Catalyst Biosciences Files Registration Statement on Behalf of Selling Stockholders	23-07-25
Catalyst Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
Catalyst Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30
Catalyst Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	23-03-29
GC Biopharma Takes Over Catalyst Biosciences' Orphan Hematology Disorder Treatment Candidates	23-03-01
Wider-Than-Expected Trade in Goods Deficit Kicks Off Tuesday's Data Dump, Stifling US Equity Futures	23-02-28
Top Premarket Gainers	23-02-28
Catalyst Biosciences, Inc. Terminates Grant Blouse from the Position as the Chief Scientific Officer	23-01-19
Top Premarket Decliners	23-01-13
Sector Update: Health Care Edging Higher at Tuesday Close	22-12-27
Sector Update: Health Care Stocks Still Struggling for Direction	22-12-27
Sector Update: Health Care	22-12-27
Catalyst Biosciences Acquires F351, Controlling Interest in Continent From GNI Group	22-12-27
GNI Group Ltd. and Catalyst Biosciences, Inc. Sign Agreements to Advance Liver Fibrosis Drug Development	22-12-27
Aeglea BioTherapeutics Promotes Linda Neuman to Chief Medical Officer	22-11-16
Catalyst Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14
Catalyst Biosciences, Inc. Declares Special One-Time Cash Dividend, Payable on September 20, 2022	22-08-25

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Catalyst Biosciences

Equities

CBIO

US14888D2080

Other languages

Filters